Compare iShares China Large-Cap ETF (FXI) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 6.5× iShares China Large-Cap ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| FXI | RPRX | |
|---|---|---|
Market Cap | $3.86B | $25.27B |
Volume | 16,323,837 | 3,671,183 |
52-Week High | $41.08 | $63.96 |
52-Week Low | $31.59 | $35.44 |
Typical Hold Time | 150 Days | 1 Days |
Sector | — | Health |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.25, up 2.48% today but facing significant technical headwinds with a bearish overall signal. The ETF shows compelling valuation metrics with a P/E ratio of 11.10 versus the S&P 500's 22.54, offering potential value for investors seeking China exposure. Recent developments include the Trump-Xi summit in late September 2026, which may provide incremental risk reduction in U.S.-China relations.
The outlook remains cautious due to China's economic challenges including industrial overcapacity and weak domestic consumption. While the valuation discount presents opportunity, geopolitical risks and technical weakness suggest limited near-term upside. Key catalysts include China's monetary policy stance and progress on trade relations with the U.S.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
